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Abstract
The advent of Next-Generation Sequencing (NGS) technologies has opened new perspec-
tives in deciphering the genetic mechanisms underlying complex diseases. Nowadays, the
amount of genomic data is massive and substantial efforts and new tools are required to
unveil the information hidden in the data. The Genomic Data Commons (GDC) Data Portal
is a platform that contains different genomic studies including the ones from The Cancer
Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective
Treatments (TARGET) initiatives, accounting for more than 40 tumor types originating from
nearly 30000 patients. Such platforms, although very attractive, must make sure the stored
data are easily accessible and adequately harmonized. Moreover, they have the primary
focus on the data storage in a unique place, and they do not provide a comprehensive toolkit
for analyses and interpretation of the data. To fulfill this urgent need, comprehensive but
easily accessible computational methods for integrative analyses of genomic data that do
not renounce a robust statistical and theoretical framework are required. In this context, the
R/Bioconductor package TCGAbiolinks was developed, offering a variety of bioinformatics
functionalities. Here we introduce new features and enhancements of TCGAbiolinks in
terms of i) more accurate and flexible pipelines for differential expression analyses, ii) differ-
ent methods for tumor purity estimation and filtering, iii) integration of normal samples from
other platforms iv) support for other genomics datasets, exemplified here by the TARGET
data. Evidence has shown that accounting for tumor purity is essential in the study of tumori-
genesis, as these factors promote confounding behavior regarding differential expression
analysis. With this in mind, we implemented these filtering procedures in TCGAbiolinks.
Moreover, a limitation of some of the TCGA datasets is the unavailability or paucity of
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corresponding normal samples. We thus integrated into TCGAbiolinks the possibility to use
normal samples from the Genotype-Tissue Expression (GTEx) project, which is another
large-scale repository cataloging gene expression from healthy individuals. The new func-
tionalities are available in the TCGAbiolinks version 2.8 and higher released in Bioconductor
version 3.7.
Author summary
The advent of Next-Generation Sequencing (NGS) technologies has been generating a
massive amount of data which require continuous efforts in developing and maintain
computational tool for data analyses. The Genomic Data Commons (GDC) Data Portal is
a platform that contains different cancer genomic studies. Such platforms have often the
primary focus on the data storage and they do not provide a comprehensive toolkit for
analyses. To fulfil this urgent need, comprehensive but accessible computational protocols
that do not renounce a robust statistical framework are thus required. In this context, we
here present the new functions of the R/Bioconductor package TCGAbiolinks to improve
the discovery of differentially expressed genes in cancer and tumor (sub)types, include the
estimate of tumor purity and tumor infiltrations, use normal samples from other plat-
forms and support more broadly other genomics datasets.
This is a PLOS Computational Biology Software paper.
Introduction
Cancer is among the leading causes of mortality worldwide. It is a complex disease where mul-
tiple different mechanisms are at play all at once. This complexity also arises from the fact that
cancer is extremely heterogeneous and can exist in distinct forms where each cancer type or
subtype can be characterized by different molecular profiles with possible consequences on
treatment and prognosis for the patient [1,2]. Advances in next-generation sequencing are cur-
rently making a massive amount of data available via the profiling of samples from cancer
patients [3–7].
In this context, numerous large-scale studies have been conducted using state-of-the-art
genome analysis technologies. One of the most important examples is The Cancer Genome
Atlas (TCGA), which started in 2006 as a pilot project aiming to collect and conduct analyses
on an unprecedented amount of clinical and molecular data including over 33 tumor types
spanning over 11,000 patients. This project has subsequently generated more than 2.5 peta-
bytes of publicly available data over the past decade [8,9]. Publicly funded by The National
Institute of Health (NIH), TCGA has made numerous discoveries regarding genomic and epi-
genomic alterations that are candidate drivers for cancer development. This was achieved
through the creation of an "atlas" and by applying large-scale genome-wide sequencing and
multidimensional analyses. These efforts have significantly contributed to high-quality oncol-
ogy studies, either led by the TCGA research network or other independent researchers [10],
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which recently culminated in 27 original publications from the Pan-Cancer TCGA initiative
[11]. In 2016, TCGA was moved under the umbrella of the broader repository Genomic Data
Commons (GDC) Data Portal [12] together with other studies.
TCGA offers two versions of public data: legacy and harmonized. The legacy data is an
unmodified collection of data that was previously maintained by the Data Coordinating Center
(DCC) using GRCh36 (hg18) and GRCh37 (hg19) as genome reference assemblies. On the
other hand, the harmonized version provides data that has been fully harmonized using
GRCh38 (hg38) as a reference genome available through the GDC portal.
Many tools have been developed to interface with TCGA data [13–25] and to help with
the aggregation, pre- and post-processing of the datasets. Among them, TCGAbiolinks was
developed as an R/Bioconductor package to address the challenges of comprehensive analyses
of TCGA data [19,20,26]. Software packages such as TCGAbiolinks regularly require
enhancements and revisions in light of new biological or methodological evidence from the
literature or new computational requirements imposed by the platforms where the data are
stored.
For example, it is well-recognized that the tumor microenvironment also includes non-
cancerous cells of which a large proportion are immune cells or cells that support blood vessels
and other normal cells [27,28]. These components can ultimately alter the outcome of genomic
analyses and the biological interpretation of the results. Recently, an extensive effort was made
to systematically quantify tumor purity with a variety of diverse methods integrated into a con-
sensus approach across TCGA cancer types [29], which the tools for analyses of TCGA data
should employ.
Other cancer genomic initiatives have been following the TCGA model, such as Therapeu-
tically Applicable Research to Generate Effective Treatments (TARGET), which is an NCI-
funded project conducting a large-scale study that seeks to unravel novel therapeutic targets,
biomarkers, and drug targets in childhood cancers by comprehensive molecular characteriza-
tion and understanding of the genomic landscape in pediatric malignancies [30]. Comprehen-
sive support for the analyses of different genomic datasets with the same workflow is thus
essential for both reproducibility and harmonization of the results.
Lastly, it is common practice to use adjacent tissue showing normal characteristics at a mac-
roscopic or histological level as a control. This advantageous practice concerning time-effi-
ciency and reduction of patient-specific bias is based on the assumption that these samples are
truly normal. Nevertheless, a tissue that is in the vicinity of or adjacent to a highly genetically
abnormal tumor is likely to show cancer-related molecular aberrations [31], biasing the com-
parison. Moreover, circulating biomolecules, originating from cancer cells, can be taken in by
the surrounding normal-like cells and alter their gene expression and processes. TCGA
includes non-tumor samples from the same cancer participants. Furthermore, the pool of
TCGA normal samples is often limited or lacking in TCGA projects. In this context, initiatives
such as Recount [32], Recount2 [33] and RNASEQDB [34] where TCGA data were integrated
with normal healthy samples from the Genotype-Tissue Expression (GTEx) project [35] have
the potential to boost the comparative analyses especially for those TCGA datasets where nor-
mal samples are underrepresented or unavailable.
In light of recent discoveries on the impact of tumor purity quantification on the samples
under investigation [29], the need for a more substantial amount of normal samples [33], as
well as the implementation of robust and statistically sound workflows for differential expres-
sion analyses [36,37] and exploration of potential sources of batch effects [38], we present
new key features and enhancements that we implemented in TCGAbiolinks version 2.8 and
higher.
New functionalities for the TCGAbiolinks package
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Results
Overview of TCGAbiolinks
For the sake of clarity, we will briefly introduce the main functions of TCGAbiolinks that are
extensively discussed in the original publication and a recently published workflow [19,20].
We advise referring directly to these publications and to the vignette on Bioconductor for more
details about the basic functionalities.
The data retrieval is handled by the three main TCGAbiolinks functions: GDCquery,
GDCdownload and GDCprepare and allows the user to interface with three main platforms: i)
TCGA, ii) TARGET and, iii) The Cancer Genome Characterization Initiative (CGCI) (https://
ocg.cancer.gov/programs/cgci). TCGAbiolinks also allows the user to interface with different
-omics data including genomics and transcriptomics, clinical and pathological data, informa-
tion on drug treatments, and subtypes.
GDCprepare allows the user to prepare the gene expression data for downstream analyses.
This step is done by restructuring the data into a SummarizedExperiment (SE) object [39] that
is easily manageable and integrable with other R/Bioconductor packages or just as a dataframe
for other forms of data manipulation, which the user can operate even decoupled from the
TCGAbiolinks package.
Moreover, TCGAbiolinks offers the option to apply normalization methods with the func-
tion TCGAanalyze_Normalization adopting the EDASeq protocol [40], to apply between-lane
normalization to adjust for distributional differences between samples or within-lane normali-
zation (to account for differences in GC content and gene length).
To guide result interpretation, the TCGAvisualize function allows the user to generate the
plots required for a comprehensive view of the analyzed data using mostly the ggplot2 package
that has incremental layer options (such as principal component analysis, pathway enrichment
analysis etc.) [41].
We extended TCGAbiolinks with new functionalities and methods that could boost the
analyses of genomic data while at the same time not necessarily limiting these functionalities
to just the TCGA initiative.
Towards a more generalized analyses of genomic data in GDC
TCGAbiolinks was initially conceived to interact with TCGA data, but the same workflow
could be in principle extended to other datasets if the functions to handle their differences in
formats and data availability are properly handled. Thus, we worked to support the SE format
for other GDC datasets, such as the ones from the TARGET consortium which is included in
TCGAbiolinks version 2.8. The SE object provides the advantage of collecting clinical informa-
tion on the samples (such as patient gender, age and treatments) and on genes (ENSEMBL and
ENTREZ IDs). One of the major problems in the study of genomic data is that they are often
stored in unconnected silos which can lead to the of stalling of advancements in the analyses
[42]. The design of the GDCprepare function of TCGAbiolinks thus nicely fulfills the need for
standardized and harmonized ways to process data from different genomics initiatives which
could find common storage in the GDC portal. Moreover, we provide the possibility to inte-
grate data from external sources and carry out joint analyses with the GDC dataset (see the
new TCGAbatch_correction function below).
Handling batch corrections in TCGAbiolinks: TCGAbatch_Correction
High-throughput sequencing and other -omics experiments are subject to unwanted sources
of variability due to the presence of hidden variables and heterogeneity. Samples are processed
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through different protocols, depending on the practices followed by each independent labora-
tory, involving time factors and multiple people orchestrating the genomic experiments.
Known as batch effects, these sources of heterogeneity can have severe impacts on the results
by statistically or biologically compromising the validity of the research [38,43,44].
Here, we created the TCGAbatch_Correction function to address and correct for different
potential sources of batch effects linked to TCGA gene expression data using the sva package
in R [38]. The sva package provides a framework for removing artifacts either by (i) estimating
surrogate variables that introduce unwanted variability into high-throughput, high-dimen-
sional datasets or (ii) using the ComBat function that employs an empirical Bayesian frame-
work to remove batch effects related to known sources [44]. Modeling for known batch effects
significantly helps to improve results by stabilizing error rates and reducing dependence on
surrogates.
In this context, TCGAbatch_Correction takes GDC gene expression data as input, extracts
all the needed metadata by parsing barcodes, corrects for a user-specified batch factor, and
also adjusts for any selected cofactor. In cases where the investigator is not interested in cor-
recting for batch effects with ComBat or this step is discouraged for the downstream analyses,
the voom (an acronym for variance modeling at the observational level) transformation can be
applied to carry out normal-based statistics on RNA-Seq gene counts [36] (see below).
The TCGAbatch_Correction function also generates plots to compare the parametric esti-
mates for the distribution of batch effects across genes and their kernel estimates. Moreover,
the so-called Q-Q plots can be produced showing the empirical data of ranked batch effects on
each gene compared to their parametric estimate. Before applying batch effect corrections, one
should investigate if there is any evidence of extreme differences between the kernel and the
parametric estimates. Such differences can show up as bimodality or severe skewness and are
due to the inability of the parametric estimation to pick up the empirical kernel behavior (an
example is provided in the case study on breast cancer below and is discussed in Fig 1).
Additionally, to make TCGA data useful in a broader context, we included the possibility of
integrating data from external sources or unpublished data in the context of publicly available
datasets such as the ones in the GDC portal. To reach this goal, we have provided the possibil-
ity within the TCGAbatch_Correction function to integrate gene expression data from external
sources (e.g GEO or unpublished datasets) and obtain a merged dataframe that can be used for
further analysis within the TCGAbiolinks pipeline such as differential expression analysis. Nev-
ertheless, we recommend the user to proceed with extreme caution with regards to the down-
stream analyses and to include the proper steps for batch corrections and harmonization of
the data when they come from different sources. It is also important to rely on data that have
been collected with the same technique and possibly the same instrument.
We provide an example for illustrative purposes only to handle the integration of datasets
from external sources with TCGA data. The TCGAbatch_Correction function can be used to
correct the integrated data for a common batch factor. In this example, we integrated the
TCGA Lung Adenocarcinoma (LUAD) with the GEO dataset GSE60052 [45] where RNA-seq
data are available for 79 samples from Small Cell Lung Cancer (SCLC) tissues and 7 normal
controls. We restricted our analysis to only tumor samples in both datasets since there were no
clear annotations for the normal samples on the GEO dataset. We queried, downloaded, and
pre-processed the TCGA-LUAD data according to the workflow used in case study 1 and 2
(see below). We log2-transformed the TCGA data to make them comparable with the GEO
data, which were released as log-transformed values. We decided to correct the data according
to the year when the sample was taken since it is the only factor in common and a suitable can-
didate to correct for technical variability in this example. We retrieved the sample year from
the downloaded TCGA clinical data using the GDCquery_clinic function. The GEO clinical
New functionalities for the TCGAbiolinks package
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Fig 1. Example of the exploration of batch effects. Four plots generated by ComBat to correct for batch effects. For the left panel
plots, the red lines are the parametric estimates, and the black lines are the kernel estimates for the distribution of effects across
genes. The right panel shows Q-Q plots with the red line for the parametric estimate and the ordered batch effects for each gene
(black points). The bottom plots show the analyses for the variances and the top plots refers to the means. Plots were generated for
batches TSS E9 and E2 to avoid batches containing only one sample.
https://doi.org/10.1371/journal.pcbi.1006701.g001
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data has been released as supplementary material to the original publication (Table S1 in [45]).
In particular, we selected all the tumor samples taken from 2010 to 2012 (three batches in total)
in both datasets. We also ensured that more than one sample was available for each batch. The
tumor samples which fulfilled the chosen batch criterion were 50 and 21 in TCGA and GEO,
respectively. Since TCGA includes 17400 and GEO 15711 genes, we selected only the features
in common (15711) by converting the TCGA Ensembl IDs to gene names using the informa-
tion stored in the SummarizedExperiment object, retrieved through the rowData function.
We then merged the two datasets and created the corresponding batch information.
This information was then provided as input to the TCGAbatch_Correction function to
produce the integrated year-corrected matrix. The script to reproduce this example is available
in the GitHub repository associated to this publication (https://github.com/ELELAB/
TCGAbiolinks_examples). We would like to stress the fact that this is just an example to show
how the function works. In a real case study, the best course of action would be to process the
external (GEO) data and the TCGA data through the same pipeline, starting from the external
raw data and calculating the read count as it is done in the harmonized or legacy version of the
TCGA data, depending on the dataset of interest for the comparison.
TCGA_MolecularSubtype
Although each cancer is believed to be a single disease, advances in the genomic field now indi-
cate that each cancer type is much more heterogeneous than previously thought and that dif-
ferent subtypes can be identified. Bioinformatics applied to genomics data can enable a
molecular understanding of the tumors across different cancer subtypes. Instead of binning all
cases and patients into a single category, differentiating the intrinsic subtypes of each cancer
has provided efficient, targeted, treatment strategies and prognoses. Cancer subtypes can be
defined according to histology or molecular profiles. Tables with general annotations from the
TCGA publications on classifications of the patients are provided by the TCGAquery_subtype
function [19]. However, the format of these data is not so easy to navigate or integrate within
other functions.
For this reason, we designed a new function TCGA_MolecularSubtype to retrieve informa-
tion on manually curated molecular subtypes for a total of 24 cancer types (Table 1). Collec-
tively, we have molecular subtype annotations for 7734 individuals. The function also allows
fetching of the subtype information not only for each cancer type, but also for each TCGA bar-
code (i.e. for each individual sample). The information used to classify cancer subtypes is the
one used (and most recently published) by the Pan-Cancer works from the TCGA consortium
(http://bioinformaticsfmrp.github.io/TCGAbiolinks/subtypes.html#pancanceratlas_subtypes:
_curated_molecular_subtypes). As an alternative, there is also the PanCancerAtlas_subtypes
function. These new functions have the advantage that the data are manually curated from
each TCGA cancer type marker paper and are thus up to date when a new paper from the
TCGA research network is published and reported in https://gdc.cancer.gov/about-data/
publications.
Recently, we showed the advantage of using these functions to have a curated matrix in one
single place for all of the subtypes. In particular, it has been applied to identify associations
between molecular subtypes and the stemness index [46] and the immune subtypes [47] of
TCGA samples.
TCGAtumor_purity
The tumor microenvironment encompases cellular and non-cellular units that play a critical
role in the initiation, progression, and metastasis of the tumor [27,29,48–50].
New functionalities for the TCGAbiolinks package
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006701 March 5, 2019 7 / 18
An important concept to remember from the TME definition is that tumor purity is
described as the proportion of carcinoma cells in a tumor sample. In previous times, tumor
purity used to be estimated through visual inspection with the assistance of a pathologist and
by image analysis. Nowadays, with the advent of computational methods and the use of geno-
mic features such as somatic mutations, DNA methylation, and somatic copy-number varia-
tion (CNV), it is feasible to estimate tumor purity [27].
To account for tumor purity in the TCGAbiolinks workflow, we designed the TCGAtu-
mor_purity function that filters data according to one of the following five methods: i) ESTI-
MATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using
Expression data) [49]; ii) ABSOLUTE to infer tumor purity from the analysis of somatic DNA
aberrations [50]; iii) LUMP (Leukocytes Unmethylation) that uses the average of 44 detected
non-methylated immune-specific CpG site; iv) IHC, that uses hematoxylin- and eosin–stained
slides, provided by the Nationwide Children’s Hospital Biospecimen Core Resource, which
Table 1. Information on molecular subtypes for TCGA cancer studies as provided by the TCGA_MolecularSubtype function.
TCGA
Abbreviation
Cancer type Number of
samples
Subtypes Selected
ACC Adrenocortical carcinoma 91 ACC.CIMP-high, ACC.CIMP-intermediate, ACC.CIMP-low
AML Acute Myeloid Leukemia 187 AML.1, AML.2, AML.3, AML.4, AML.5, AML.6, AML.7
BLCA Bladder Urothelial Carcinoma 129 BLCA.1, BLCA.2, BLCA.3, BLCA.4
BRCA Breast invasive carcinoma 1218 BRCA.Basal, BRCA.Her2, BRCA.LumA, BRCA.LumB, BRCA.Normal
COAD Colon adenocarcinoma 341 GI.CIN, GI.GS, GI.HM-indel, GI.HM-SNV
ESCA Esophageal carcinoma 169 GI.CIN, GI.ESCC, GI.GS, GI.HM-indel, GI.HM-SNV
GBM Glioblastoma multiforme 606 GBM_LGG.Classic-like, GBM_LGG.Codel, GBM_LGG.G-CIMP-high, GBM_LGG.G-CIMP-
low, GBM_LGG.LGm6-GBM, GBM_LGG.Mesenchymal-like
HNSC Head and Neck squamous cell
carcinoma
279 HNSC.Atypical, HNSC.Basal, HNSC.Classical, HNSC.Mesenchymal
KICH Kidney Chromophobe 66 KICH.Eosin.0, KICH.Eosin.1
KIRC Kidney renal clear cell
carcinoma
442 KIRC.1, KIRC.2, KIRC.3, KIRC.4
KIRP Kidney renal papillary cell
carcinoma
161 KIRP.C1, KIRP.C2a, KIRP.C2b, KIRP.C2c - CIMP
LGG Brain Lower Grade Glioma 516 GBM_LGG.Classic-like, GBM_LGG.Codel, GBM_LGG.G-CIMP-high, GBM_LGG.G-CIMP-
low, GBM_LGG.Mesenchymal-like, GBM_LGG.PA-like
LIHC Liver hepatocellular carcinoma 196 LIHC.iCluster:1, LIHC.iCluster:2, LIHC.iCluster:3
LUAD Lung adenocarcinoma 230 LUAD.1, LUAD.2, LUAD.3, LUAD.4, LUAD.5, LUAD.6
LUSC Lung squamous cell carcinoma 178 LUSC.basal, LUSC.classical, LUSC.primitive, LUSC.secretory
OVCA Ovarian serous
cystadenocarcinoma
489 OVCA.Differentiated, OVCA.Immunoreactive, OVCA.Mesenchymal, OVCA.Proliferative
PCPG Pheochromocytoma and
Paraganglioma
178 PCPG.Cortical admixture, PCPG.Pseudohypoxia, PCPG.Wnt-altered
PRAD Prostate adenocarcinoma 333 PRAD.1-ERG, PRAD.2-ETV1, PRAD.3-ETV4, PRAD.4-FLI1, PRAD.5-SPOP, PRAD.6-FOXA1,
PRAD.7-IDH1, PRAD.8-other
READ Rectum adenocarcinoma 118 GI.CIN, GI.GS, GI.HM-indel, GI.HM-SNV
SKCM Skin Cutaneous Melanoma 333 SKCM.-, SKCM.BRAF_Hotspot_Mutants, SKCM.NF1_Any_Mutants, SKCM.
RAS_Hotspot_Mutants, SKCM.Triple_WT
STAD Stomach adenocarcinoma 383 GI.CIN, GI.EBV, GI.GS, GI.HM-indel, GI.HM-SNV
THCA Thyroid carcinoma 496 THCA.1, THCA.2, THCA.3, THCA.4, THCA.5
UCEC Uterine Corpus Endometrial
Carcinoma
538 UCEC.CN_HIGH, UCEC.CN_LOW, UCEC.MSI, UCEC.POLE
UCS Uterine Carcinosarcoma 57 UCS.1, UCS.2
https://doi.org/10.1371/journal.pcbi.1006701.t001
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are processed using image analysis techniques to generate a tumor purity estimate; v) Consen-
sus measurement of Purity Estimation (CPE), a consensus estimate from the four methods
mentioned above [29]. CPE is calculated as the median purity level after normalization of the
values from the four methods and correcting for the means and standard deviations and it is
the default option of the TCGAtumor_purity function.
TCGAanalyze_DEA extension
We revised and expanded the pre-existing TCGAbiolinks function TCGAanalyze_DEA that
performs differential expression analysis (DEA) by calling the commonly used R package,
edgeR [37]. In the former version of TCGAbiolinks, only a pairwise approach (for example,
control versus case) was applied to a matrix of count data and samples to extract differentially
expressed genes (DEGs). More specifically, the former TCGAanalyze_DEA function imple-
mented two options: (i) the exactTest framework for a simple pairwise comparison or (ii) the
GLM (Generalized Linear Model) where a user faces a more complex experimental design
involving multiple factors. However, in the latter case, the design of the function allowed the
user to provide arguments only for case and control thereby being incompatible with multifac-
tor experiments, for which GLM methods are particularly suited [51]. We thus implemented a
different design to improve the functionality of TCGAanalyze_DEA by providing the ability to
analyze RNA-Seq data in a more general and comprehensive way. The user is now able to
apply edgeR with a more sophisticated design matrix and to use the limma-voom method, an
emerging gold standard for RNA-Seq data [52]. Furthermore, modeling multifactor experi-
ments and correcting for batch effects related to TCGA samples is now an option in the
updated version of TCGAanalyze_DEA. The new arguments for the function allow to use dif-
ferent sources of batch effects in the design matrix, such as the plates, the TSS (Tissue Source
Site), the year in which the sample was taken and the patient factor in the cases of paired nor-
mal and tumor samples. Moreover, an option is provided to apply two different pipelines to
the study of paired or unpaired samples, namely limma-voom and limma-trend pipelines. A
contrast formula is provided to determine coefficients and design contrasts in a customized
way, as well as the possibility to model a multifactor experimental design. In particular, the
model formula for the edgeR pipeline is designed so that the intercept is set to 0 when there are
multiple conditions (such as the molecular subtypes) or contrasts to be explored, following the
recommendation of edgeR developers.
The function returns two types of objects: i) a table with DEGs containing logFC, logCPM,
p-value, and FDR corrected p-values in cases of pairwise comparison for each gene, and/or ii)
a list object containing multiple tables for DEGs according to each contrast specified in the
contrast.formula argument.
TCGAquery_recount2
The Recount project was created as an online resource that comprises gene count matrices
built from 8 billion reads using 475 samples gathered from 18 published studies [32]. This atlas
of RNA-Seq count matrices improves the process of data acquisition and allows cross-study
comparisons since all of the count matrices were produced from one single pipeline reducing
batch effects and promoting alternative normalization. Recount was then extended to Recount2
consisting of more than 4.4 trillion reads using 70,603 human RNA-seq samples from the
Sequence Read Archive (SRA), GTEx, and TCGA that were uniformly processed, quantified
with Rail-RNA [51], and included in the recent Recount2 interface [33].
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For this reason, TCGAquery_recount2 queries GTEx and TCGA data for all tissues available
in the Recount2 platform, providing the user with the flexibility to decide which tissue source
to use for the calculations.
TCGAquery_recount2 integrates normal samples from GTEx and normal samples from
TCGA. If the user wants to use GTEx alone as a source of normal samples, an ad hoc curation
of the dataset will be needed before applying the functions for pre-processing of the data and
downstream analyses with TCGAbiolinks.
Below, we illustrate two case studies as an example of the usage of the new functions and
the interpretation of their results.
Case study 1—A protocol for pre-processing and differential expression
analysis of TCGA-BRCA luminal subtypes
The TCGA Breast Invasive Carcinoma (BRCA) dataset is the ideal case study to illustrate the
new functionalities of TCGAbiolinks (see Fig 2 for a workflow illustrating this case study and
the new functions).
We carried out the query, download and pre-processing of the TCGA-BRCA RNA-Seq
data through the GDC portal with a variation of the workflow suggested for the previous ver-
sions of the TCGAbiolinks software (see the script reported in https://github.com/ELELAB/
TCGAbiolinks_examples). As an example, out of a possible 1222 BRCA samples available in
the GDC portal, we restricted our analysis to 100 tumor (TP) samples and 100 normal (NT)
samples respectively.
We constructed the SE object as the starting structure displaying information for both
genes and samples with gene expression tables of HTSeq-based counts from reads harmonized
and aligned to hg38 genome assembly. Afterwards, we applied an Array Array Intensity corre-
lation (AAIC) to pinpoint samples with low correlation (0.6 threshold for this study) using
TCGAanalyze_Preprocessing, which generates a count matrix ready to be used as input for the
downstream analysis pipeline. In addition, we normalized the gene counts for GC-content
using TCGAanalyze_Normalization adopting EDASeq protocol incorporated with
TCGAbiolinks.
An exploratory data analysis (EDA) step is now possible within TCGAbiolinks to help to
understand the quality of the data and to identify possible anomalies or cofounder effects. This
can be done by estimating the presence of batch effects through the plots provided by the Com-
Bat function, as described above. We can call the TCGAbatch_Correction function on a log2
transformed instance of the count matrix. For the sake of clarity, we used batch correction on
TSS as a cofounder factor along with accounting for one covariate (cancer versus normal) and
only two batches were retained. The results are reported in Fig 1.
According to the standard defined by the TCGA consortium, 60% tumor purity is the rec-
ommended threshold for analyses [29]. Thus, we applied a filtering step using the TCGAtu-
mor_purity function of TCGAbiolinks whereby tumor samples that show a purity of less than
60% median CPE are discarded from the analysis. As a result, a total of 26 samples were dis-
carded with the goal of reducing the confounding effect of tumor purity on genomic analyses.
We then applied the new TCGAanalyze_DEA function to exploit the power of generalized
linear models beyond the control versus case scheme. As an illustrative case, we queried the
PAM50 classification [52] for each of the samples through TCGA_MolecularSubtype. We iden-
tified 86 samples with information on subtypes. The output is then provided to the DEA
method so the customizable contrast.formula argument can contain the formula for designing
the contrasts. Beforehand, the data is normalized for GC-content, as explained above. As a
final step, quantile filtering is applied with a cutoff of 25%, as suggested by the original
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Fig 2. The workflow illustrates the steps and TCGAbiolinks functions to be used for case study 1 on TCGA-BRCA
luminal subtypes.
https://doi.org/10.1371/journal.pcbi.1006701.g002
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TCGAbiolinks workflow. Within the TCGAanalyze_DEA function, it is also possible to per-
form a voom transformation of the count data, as detailed above. In Fig 3A, we show the results
of the new implementation of the TCGAanalyze_DEA function as a volcano plot. The genes
with highest logFC are shown (using logFC higher or lower than 6 in absolute value as a cut-
off). We then compared these results to the ones produced using DEA as implemented in
edgeR within the TCGAanalyze_DEA (see volcano plot in Fig 3B). We calculated the correla-
tion between the top 500 DE genes identified by the two methods (Fig 3C) which resulted in a
Pearson Correlation Coefficient higher than 0.9. We then quantitatively compared the results
of the two methods calculating the intersect with UpSetR [53] (Fig 3D). The two methods are
in good agreement showing 1629 and 1365 down- and up-regulated genes in common, which
account for approximately 90% of the total DE genes. With both methods we identified up-
regulated matrix metalloproteinases (such as MMP11 and MMP13) which are a class of
enzyme known to be involved in cancer invasion and metastasis and have been linked to breast
cancer outcomes [54]. We also identified different collagen proteins (such as COL10A1 and
COL11A1) that are up-regulated in luminal versus normal breast cancer samples. Those pro-
teins are important for the composition of the extracellular matrix (ECM). Changes in the
amount or composition of the ECM have been considered a hallmark of tumor development
[55]. COL11A1 and COL10A1 have recently been proposed as markers to discriminate
between breast cancer and healthy tissues and could be helpful in the diagnosis of suspicious
breast nodules [56].
Fig 3. DEA analyses of TCGA-BRCA data comparing luminal subtypes with normal samples. A-B) Volcano plots are shown
where only those genes with logFC higher than 6 or lower than -6 are labelled and only the significant up- or down-regulated genes
are shown as dots. We carried out DEA using the limma (A) or edgeR pipelines (B) of TCGAbiolinks. C) The correlation plot
between the logFC estimated by the two pipelines for the top 500 DE genes is shown. The genes discussed in the main text are
highlighted in bold. D) The intersect between all the DE genes estimated by the two pipelines is shown using UpSet.
https://doi.org/10.1371/journal.pcbi.1006701.g003
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Case study 2—Uterine cancer dataset exploiting Recount2
One issue that can be encountered when planning DEA of TCGA data is the fact that some
projects on the GDC portal do not contain normal control samples for the comparison with
the tumor samples. As explained previously, it is now possible to query data from the Recount2
platform to increase the pool of normal samples and apply the DEA pipelines of TCGAbiolinks
(see Fig 4A for a workflow).
For this case study, we used the TCGA Uterine Carcinosarcoma (UCS) dataset to illustrate
this application. We queried, downloaded, and pre-processed the data using a similar work-
flow to our previous case study, and then GTEx healthy uterine tissues were used as a source of
normal samples for DEA. Concerning the type of count data queried, it was similarly harmo-
nized HTSeq counts and aligned to the hg38 genome assembly (see the script reported in
https://github.com/ELELAB/TCGAbiolinks_examples). We used the TCGAquery_recount2
function to download tumor and normal uterine samples from the Recount2 platform as Ran-
ged Summarized Experiment (RSE) objects.
Before engaging in DEA, one should keep in mind that the Recount2 resource contains
reads, some of them soft-clipped, aligned to Gencode version 25 hg38 using the splice-aware
Fig 4. DE genes in uterine cancer compared to healthy uterine tissue samples. A) The workflow illustrates the steps and
TCGAbiolinks functions to be used for this case study. B-C) In the volcano plot, the up-regulated genes with logFC higher than 5 (B)
or the down-regulated genes with logFC lower than -5 (C) are shown as a result of DEA carried out using the limma pipeline
comparing primary tumor samples from TCGA-UCS and normal uterine tissue samples from GTEx.
https://doi.org/10.1371/journal.pcbi.1006701.g004
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Rail-RNA aligner. Moreover, the RSE shows coverage counts instead of standard read count
matrices. Since most methods are adapted to read count matrices, there are some highly rec-
ommended transformations to perform before commencing with DEA. The user should
extract sample metadata from RSE objects regarding read length and mapped read counts to
pre-process the data. If one provides a target library size (40 million reads by default), coverage
counts can be scaled to read counts usable for classic DEA methods according to Eq (1) (possi-
bly with the need to round the counts since the result might not be of an integer type).
Xn
i
coverage
Read Length
�
target
mapped
¼ scaled read counts ð1Þ
The denominator is the sum of the coverage for all base-pairs of the genome which can be
replaced by the Area under Curve (AUC) [57]. It is possible to use the function scale_counts
from the recount package. After that, we merged the two prepared gene count matrices, nor-
malized for GC-content and applied the quantile filtering with a 25% cut-off. The data were
then loaded into the TCGAanalyze_DEA function for comparison of normal samples versus
cancer samples using the limma-voom pipeline. Two volcano plots depicting the top up- and
down-regulated genes are shown in Fig 4B and 4C, respectively. As an example, we identified
the up-regulated gene ADAM28 in the UCS tumor samples when compared to the normal
ones (logFC = 3.13, thus not shown in Fig 4B). ADAM28 belongs to the ADAM family of dis-
integrins and metalloproteinases which are involved in important biological events such as cell
adhesion, fusion, migration and membrane protein shedding and proteolysis. They are often
overexpressed in tumors and contribute to the promotion of cell growth and invasion [58].
Among the top up-regulated genes in UCS, we also identified other key players in cell adhesion
such as the cadherin CDH1 [58] shown in Fig 4B.
Availability and future directions
The functions illustrated in this manuscript are now available in version 2.8 of TCGAbiolinks
on Bioconductor version 3.7 (https://bioconductor.org/packages/release/bioc/html/
TCGAbiolinks.html ), as well as through the two Github repositories (https://github.com/
ELELAB/TCGAbiolinks and https://github.com/BioinformaticsFMRP/TCGAbiolinks/).
In addition, we provide daily scientific advice to the Github community within the ‘issues’
forum (https://github.com/BioinformaticsFMRP/TCGAbiolinks/issues) to solve both software
bugs and to provide new functionalities needed or requested by the Github community. This
forum is also a place where TCGAbiolinks users can share and discuss their experience with
their analyses with our team and/or other Github users.
The newly developed functions will for the first time allow users to fully appreciate the effect
of using genuinely healthy samples or normal tumor-adjacent samples as a control as well as
the benefits of correcting for the tumor purity of the samples. We provide a more robust and
comprehensive workflow to carry out differential expression analysis with two different meth-
ods and a customizable design matrix, as well as the capability to handle batch corrections.
Overall, this will provide the community with the possibility to use the same framework for
vital analyses such as the benchmarking of differential expression methods.
(https://bioconductor.org/packages/release/bioc/vignettes/TCGAbiolinks/inst/doc/
extension.html).
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